The differences between the generics industry and other pharma companies wouldn’t exist without patents – legal titles that exclude others from producing or using an invention or innovation ...

The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve ...

arguing that four out of 10 products covered by the scheme are actually branded generics or biosimilars, but was prevented from doing so by a High Court ruling. Samuels said today that the BGMA ...